| Lead Manager/ | # of | Price Range | Dollar | SCOOP | ||
| New Filings (Proposed Symbol) | Joint-Lead Managers | Shares | Low | High | Volume | Ratings |
| CollPlant Holdings (CLGN) | Ladenburg Thalmann | 0.00 | $0.00 | $0.00 | $25.00 | N/C |
| N/C = No Call – Stock is traded on the AIM market of the London Stock Exchange | ||||||
| Postponed | ||||||
| None | ||||||
| Withdrawn | ||||||
| Centennial Resource Development (CDEV) | Credit Suisse/ Barclays | $100.00 | n.a. | |||
| n.a. (not available) | ||||||
| New Terms | ||||||
| Acushnet Holdings (GOLF) | J.P. Morgan/ Morgan Stanley/ Nomura/ UBS Investment Bank | 19.33 | $21.00 | $24.00 | $435.00 | S/O |
| BlackLine (BL) | Goldman Sachs/ J.P. Morgan | 8.60 | $13.00 | $15.00 | $120.40 | S/O |
| GDS Holdings Ltd. (GDS) | Credit Suisse/ J.P. Morgan | 19.25 | $12.00 | $14.00 | $250.25 | S/O |
| GTY Technology Holdings (GTYHU) (u) | Citigroup | 30.00 | $10.00 | $10.00 | $300.00 | S/O |
| Myovant Sciences Ltd. (MYOV) | Citigroup/ Cowen and Company/ Evercore ISI/ Barclays | 13.00 | $12.00 | $15.00 | $175.50 | S/O |
| Quantenna Communications (QNTA) | Morgan Stanley/ Barclays/ Deutsche Bank Securities | 6.70 | $14.00 | $16.00 | $100.50 | S/O |
| Ra Pharmaceuticals (RARX) | Credit Suisse/ Jefferies/ BMO Capital Markets | 5.80 | $12.00 | $14.00 | $75.40 | S/O |
| SenesTech (SNES) | Roth Capital Partners | 2.00 | $12.00 | $14.00 | $26.00 | S/O |
| S/O (Subscribers Only) | ||||||
| IPOs Priced | Lead | Shares | Amount | Offer | Close | % |
| Week of Oct. 17, 2016 | Manager(s) | Offered | Raised | Price | 10/21/16 | Change |
| iRhythm Technologies (IRTC) | J.P. Morgan/ Morgan Stanley | 6.29 | $107.00 | $17.00 | $25.79 | 51.71% |
| CRISPR Therapeutics AG (CRSP) | Citigroup/ Piper Jaffray/ Barclays | 4.00 | $56.00 | $14.00 | $13.82 | -1.29% |
| Forterra (FRTA) | Goldman Sachs/ Citigroup/ Credit Suisse | 18.42 | $331.56 | $18.00 | $17.00 | -5.56% |
